ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 2154

Journal of Biotechnology & Biomaterials received 2154 citations as per Google Scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Recommended Journals
Share This Page

Human papillomavirus (HPV): Systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus

Joint Event on 22nd Global Congress on Biotechnology & 5th International Conference on Enzymology and Protein Chemistry

Hanan Polansky, Edan Itzkovitz and Adrian Javaherian

The Center for the Biology of Chronic Disease, USA

Posters & Accepted Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X-C2-116

Abstract
This paper reports the results of a clinical study that tested the effect of systemic treatment with the botanical product Gene- Eden-VIR/Novirin on the clearance rate (also called time to clearance) of the human papillomavirus (HPV). The study compared the clearance rate in treated and untreated individuals suffering from a symptomatic HPV infection. The mean time to clearance in Gene-Eden-VIR/Novirin treated individuals was 5.1 months or 151.5 days (95% CI: 4.2-5.9 months or 95% CI: 125.7-177.3 days respectively). The median time to clearance was 3.5 months. The mean time to clearance in the five untreated groups ranged from 6.9 to 20.0 months (P<0.0001 for the difference between treatment group and each untreated group). Also, 100% of the participants in the treatment group were HPV free at the end of 12 months vs., 53%, 52%, 65%, 20%, and 77% in the untreated control groups. The treated participants reported no adverse experiences. This clinical study has two major contributions. First, it showed that systemic treatment with the natural Gene-Eden-VIR/Novirin decreased the time of HPV clearance, increased the percentage of HPV free individuals and caused no adverse experiences in individuals suffering from a symptomatic HPV infection. Since, there are no other systemic treatments for symptomatic HPV infections, this study presents highly valuable information on the clinical effects of the first treatment in this category. Secondly, the study presents a new method for conducting clinical studies that addresses one of the major deficiencies associated with the practice of the randomized controlled trial method.
Biography

E-mail: hpolansky@cbcd.net

 

Top